<DOC>
	<DOCNO>NCT00369265</DOCNO>
	<brief_summary>The purpose study determine whether Lansoprazole 30mg take twice daily effective treatment laryngitis due gastroesophageal reflux .</brief_summary>
	<brief_title>Safety Efficacy Lansoprazole 30mg Twice Daily Treatment Laryngitis Associated With Gastroesophageal Reflux</brief_title>
	<detailed_description>The investigator propose study effect Lansoprazole 30 mg bid therapy vs. placebo patient present symptom characteristic reflux laryngitis . The efficacy Lansoprazole 30 mg bid heal improve reflux laryngitis determine . For purpose study , heal reflux laryngitis define improvement resolution arytenoid erythema improvement symptom . Improved reflux laryngitis define improvement two follow area : arytenoid erythema ; voice quality assess patient health care provider ; , improvement/resolution relate symptom ( throat clearing , cough , etc. ) . The impact Lansoprazole 30 mg bid therapy quality life evaluate preliminary fashion .</detailed_description>
	<mesh_term>Gastroesophageal Reflux</mesh_term>
	<mesh_term>Laryngopharyngeal Reflux</mesh_term>
	<mesh_term>Laryngitis</mesh_term>
	<mesh_term>Lansoprazole</mesh_term>
	<mesh_term>Dexlansoprazole</mesh_term>
	<criteria>Vocal skill necessary complete test procedure reliably . Voice complaint and/or symptom suggestive reflux laryngitis Signed informed consent At least 18 year age . Complete medical history physical examination within 30 day prior initiation study drug . Laryngoscopy document laryngeal pathology compatible moderate severe reflux laryngitis ( &gt; grade 3 arytenoid erythema ) within 30 day initiation study drug . Gastroesophageal reflux confirm 24hour ( minimum 16 hour require inclusion ) pH impedance monitor . Ambulatory outpatient status . If female , negative pregnancy test screen visit either : ) surgically sterilize ( bilateral tubal ligation hysterectomy ) , ii ) least 1 year postmenopausal , iii ) use acceptable method contraception presence childbearing potential . Concurrent laryngeal disease , disease treatment would interfere evaluation study result . For example , patient mass lesion laryngeal cyst laryngeal carcinoma exclude . Patients acute laryngeal infection acute laryngeal allergy exclude condition resolve ; may consider inclusion thereafter . Any upper gastroenterological esophageal surgery except simple oversew perforated ulcer . Active substance abuse . Tobacco use . Known hypersensitivity allergy protein pump inhibitor . ALT ( SGPT ) AST ( SGOT ) great 2 time upper limit normal . Renal impairment ( serum creatinine &gt; 2.0 mg/dl ) . Any clinically significant , unstable medical condition . Use proton pump inhibitor within 7 day prior 24hour pH impedance monitoring baseline strobovideolaryngoscopy , use H2 receptor antagonist 48 hour prior 24hour pH impedance monitoring baseline strobovideolaryngoscopy . Use investigational drug participation investigational study , within 30 day prior start study drug . Previous participation study . Pregnant woman . Women breast feeding infant . Inability refusal follow direction . Open label substudy inclusion exclusion criterion , exception subject : 1 ) Clinical diagnosis nonacid reflux , less 5 episode proximal acid reflux , 2 ) Symptoms sign consistent gastroesophageal reflux .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>89 Years</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>Gastroesophageal reflux</keyword>
	<keyword>Laryngitis</keyword>
	<keyword>Hoarseness</keyword>
	<keyword>Dysphonia</keyword>
	<keyword>Proton pump inhibitor</keyword>
</DOC>